Montuschi Johnson M, Rennard S. 2001. Alternative mechanisms for long-acting β -agonists in COPD. Chest, 120:258-70. 2 Jones PW, Willits LR, Burge PS, et al. 2003. Disease severity and effect of ﬂuticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J, 21:68-73. Jorenby DE, Leischow SJ, Nides MA, et al. 1999. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med, 340:685-91. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inﬂammatory indices in asthma and COPD. Am J Respir Crit Care Med, 155:542-8. Kirsten DK, Wegner RE, Jorres RA, et al. 1994. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest, 104:1101-7. Kume H, Hall IP, Washabau RJ, et al. 1994. Beta-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and -independent mechanisms. J Clin Invest, 93:371-9. Lipworth BJ. 2005. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, 365:167-75. [LHSRG] The Lung Health Study Research Group II. 2000. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med, 343:1902-9. Lloberes P, Ramis L, Montserrat JM, et al. 1988. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J, 1:536-9. MacNee W. 2002. Acute exacerbations of COPD. Consensus conference on management of chronic obstructive pulmonary disease. J R Coll Physicians Edinb, 32:16-26. MacNee W, Calverley PM. 2003. Chronic obstructive pulmonary disease. 7: Management of COPD. Thorax, 58:261-5. Mahler DA, Donohue JF, Barbee RA, et al. 1999. Efﬁcacy of salmeterol xinafoate in the treatment of COPD. Chest, 115:957-65. Mahler DA, Wire P, Horstman D, et al. 2002. Effectiveness of ﬂuticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 166:1084-91. Mahon JL, Laupacis A, Hodder RV, et al. 1999. Theophylline for irreversible chronic airﬂow limitation: a randomized study comparing n of 1 trials to standard practice. Chest, 115:38-48. Maltais F, Ostinelli J, Bourbeau J, et al. 2002. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med, 165:698-703. Manning CD, Burman M, Christensen SB, et al. 1999. Suppression of hu- man inﬂammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol, 128:1393-8. McKay SE, Howie CA, Thomson AH, et al. 1993. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax, 48:227-32. McNicholas WT, Calverley PM, Lee A, 2004. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J, 23:825-31. Moayyedi P, Congleton J Page RL, et al. 1995. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax, 50:834-7. Monso E, Ruiz J, Rosell A, et al. 1995. Bacterial infection in chronicobstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med, 152:1316-20. Mulloy E, McNicholas WT. 1993. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis, 148:1030-6. Murciano D, Aubier M, Lecocguic Y, et al. 1984. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med, 311:349-53. Murciano D, Auclair MH, Pariente R, et al. 1989. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med, 320:1521-5. Nannini L, Cated CJ, Lasserson TJ, et al. 2004. Combined corticosteroid and long acting β-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3:CD003794. Nichol KL, Margolis KL, Wuorenma J, et al. 1994. The efﬁcacy and cost effectiveness of vaccination against inﬂuenza among elderly persons living in the community. N Engl J Med, 331:778-84. Niewoehner DE, Erbland ML, Deupree RH, et al. 1999. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med, 340:1941-7. Nishimura K, Koyama H, Ikeda A, et al. 1995. The additive effect of theophylline on high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest, 107:718-23. [NPG] The Nebuliser Project Group of the British Thoracic Society Standards and Care Committee. 1997. BTS Guidelines on current best practice for nebuliser treatment. Thorax, 52(Suppl. 2):S1-106. Ojoo JC, Moon T, McGlone S, et al. 2002. Patients’ and carers’ preferences in two models of care for acute exacerbations of COPD: results of a randomised controlled trial. Thorax, 57:167-9. Paggiaro PL, Dahle R, Bakran I, et al. 1998. Multicentre randomised placebo-controlled trial of inhaled ﬂuticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet, 351:773-80. Pauwels RA, Lofdahl CG, Laitinen LA, et al. 1999. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med, 340:1948-53. Plant PK, Owen JL, Elliott MW. 2000a. One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administra- tion. Thorax, 55:550-4. Plant PK, Owen JL, Elliott MW. 2000b. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicenter randomised controlled trial. Lancet, 355:1931-5. Poole PJ, Black PN. 2000. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2:CD001287. Rabe KF, Bateman ED, O’Donnell D, et al. 2005. Roﬂumilast – an oral anti-inﬂammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet, 366:563-71. Rahman I. 2006. Antioxidant therapies in COPD. Int J COPD, 1:15-31. Rennard SI. 2004. Treatment of stable chronic obstructive pulmonary disease. Lancet, 364:791-802. Rennard SI, Anderson W, ZuWallack R, et al. 2001. Use of a long-acting inhaled β -adrenergic agonist, salmeterol xinafoate, in patients with 2 chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:1087-92. Rennard SI, Schachter N, Strek M, et al. 2006. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest, 129:56-66. Rodriguez-Roisin R. 2000. Toward a consensus deﬁnition for COPD exacerbations. Chest, 117(Suppl 2):398-401S. [RS] Respiratory system. 2003. In: British National Formulary, 45th ed. London: Pharmaceutical Pr, 131-65. Sachs FL. 1981. Chronic bronchitis. Clin Chest Med, 2:79-89. Seale JP. 1988. Whither β-adrenoceptor agonists in the treatment of asthma. Prog Clin Biol Res, 263:367-77 Seemungal TA, Donaldson GC, Paul EA, et al. 1998. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonay disease. Am J Respir Crit Care Med, 157:1418-22. 422 International Journal of COPD 2006:1(4)